PMID- 30589533
OWN - NLM
STAT- MEDLINE
DCOM- 20200611
LR  - 20200611
IS  - 1948-7193 (Electronic)
IS  - 1948-7193 (Linking)
VI  - 10
IP  - 7
DP  - 2019 Jul 17
TI  - Role of Serotonin Transporter and Receptor Gene Variations in the Acute Effects 
      of MDMA in Healthy Subjects.
PG  - 3120-3131
LID - 10.1021/acschemneuro.8b00590 [doi]
AB  - Methylenedioxymethamphetamine (MDMA; ecstasy) is used recreationally and has been 
      investigated as an adjunct to psychotherapy. Most acute effects of MDMA can be 
      attributed to activation of the serotonin (5-hydroxytryptamine [5-HT]) system. 
      Genetic variants, such as single-nucleotide polymorphisms (SNPs) and polymorphic 
      regions in 5-HT system genes, may contribute to interindividual differences in 
      the acute effects of MDMA. We characterized the effects of common genetic 
      variants within selected genes that encode the 5-HT system (TPH1 [tryptophan 
      5-hydroxylase 1] rs1800532 and rs1799913, TPH2 [tryptophan 5-hydroxylase 2] 
      rs7305115, HTR1A [5-HT(1A) receptor] rs6295, HTR1B [5-HT(1B) receptor] rs6296, 
      HTR2A [5-HT(2A) receptor] rs6313, and SLC6A4 [serotonin transporter] 5-HTTLPR and 
      rs25531) on the physiological and subjective response to 125 mg of MDMA compared 
      with placebo in 124 healthy subjects. Data were pooled from eight randomized, 
      double-blind, placebo-controlled studies that were conducted in the same 
      laboratory. TPH2 rs7305115, HTR2A rs6313, and SLC6A4 5-HTTLPR polymorphisms 
      tended to moderately alter some effects of MDMA. However, after correcting for 
      multiple comparisons, none of the tested genetic polymorphisms significantly 
      influenced the response to MDMA. Variations in genes that encode key targets in 
      the 5-HT system did not significantly influence the effects of MDMA in healthy 
      subjects. Interindividual differences in the 5-HT system may thus play a marginal 
      role when MDMA is used recreationally or therapeutically.
FAU - Vizeli, Patrick
AU  - Vizeli P
AD  - Division of Clinical Pharmacology and Toxicology, Department of Biomedicine, 
      Department of Clinical Research , University Hospital Basel, University of Basel 
      , Basel CH-4056 , Switzerland.
FAU - Meyer Zu Schwabedissen, Henriette E
AU  - Meyer Zu Schwabedissen HE
AUID- ORCID: 0000-0003-0458-4579
AD  - Biopharmacy, Department of Pharmaceutical Sciences , University of Basel , Basel 
      4056 , Switzerland.
FAU - Liechti, Matthias E
AU  - Liechti ME
AUID- ORCID: 0000-0002-1765-9659
AD  - Division of Clinical Pharmacology and Toxicology, Department of Biomedicine, 
      Department of Clinical Research , University Hospital Basel, University of Basel 
      , Basel CH-4056 , Switzerland.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20190110
PL  - United States
TA  - ACS Chem Neurosci
JT  - ACS chemical neuroscience
JID - 101525337
RN  - 0 (Receptors, Serotonin)
RN  - 0 (Serotonin Agents)
RN  - 0 (Serotonin Plasma Membrane Transport Proteins)
RN  - EC 1.14.16.4 (Tryptophan Hydroxylase)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Affect/drug effects
MH  - Alleles
MH  - Blood Pressure/drug effects
MH  - Body Temperature/drug effects
MH  - Double-Blind Method
MH  - Female
MH  - Genetic Association Studies
MH  - Healthy Volunteers
MH  - Humans
MH  - Male
MH  - N-Methyl-3,4-methylenedioxyamphetamine/*pharmacology
MH  - *Polymorphism, Single Nucleotide
MH  - Receptors, Serotonin/*genetics
MH  - Serotonin Agents/*pharmacology
MH  - Serotonin Plasma Membrane Transport Proteins/*genetics
MH  - Tryptophan Hydroxylase/*genetics
MH  - Young Adult
OTO - NOTNLM
OT  - MDMA
OT  - pharmacogenetics
OT  - serotonin system
EDAT- 2018/12/28 06:00
MHDA- 2020/06/12 06:00
CRDT- 2018/12/28 06:00
PHST- 2018/12/28 06:00 [pubmed]
PHST- 2020/06/12 06:00 [medline]
PHST- 2018/12/28 06:00 [entrez]
AID - 10.1021/acschemneuro.8b00590 [doi]
PST - ppublish
SO  - ACS Chem Neurosci. 2019 Jul 17;10(7):3120-3131. doi: 
      10.1021/acschemneuro.8b00590. Epub 2019 Jan 10.